プロの翻訳者、企業、ウェブページから自由に利用できる翻訳レポジトリまで。
under hver organklasse er bivirkninger listet med faldende frekvens for monoterapeutisk rosiglitazon behandlingsregime.
within each system organ class, adverse reactions are presented in the table by decreasing frequency for the rosiglitazone monotherapy treatment regimen.
最終更新: 2012-04-11
使用頻度: 9
品質:
tysabri er indiceret som en monoterapeutisk sygdomsmodificerende behandling hos patienter med relapsing- remitting multipel sklerose for at forhindre attakker og for at forsinke progression af handikapudvikling.
tysabri is indicated as a single disease modifying therapy in relapsing remitting multiple sclerosis to prevent relapses and delay progression of disability.
最終更新: 2012-04-12
使用頻度: 3
品質:
tysabri er indiceret som en monoterapeutisk sygdomsmodificerende behandling af meget aktiv relapsing- remitting multipel sklerose (ms) hos følgende patientgrupper:
tysabri is indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following patient groups:
最終更新: 2012-04-12
使用頻度: 3
品質:
under hver organklasse er bivirkningerne stillet op efter faldende frekvens for det monoterapeutiske rosiglitazon-behandlingsregime.
within each system organ class, adverse reactions are presented in the table by decreasing frequency for the rosiglitazone monotherapy treatment regimen.
最終更新: 2017-04-26
使用頻度: 3
品質: